



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/724,900

12/02/2003

J. Glenn Morris

62610.000035

2442

21967 7590 10/16/2007

HUNTON & WILLIAMS LLP
INTELLECTUAL PROPERTY DEPARTMENT
1900 K STREET, N.W.
SUITE 1200
WASHINGTON, DC 20006-1109

EXAMINER

JOIKE, MICHELE K

ART UNIT

PAPER NUMBER

1636

MAIL DATE

DELIVERY MODE

10/16/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/724,900

Applicant(s)

MORRIS ET AL.

Examiner

Michele K. Joike, Ph.D.

Art Unit

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 July 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-21 and 29-52 is/are pending in the application.
- 4a) Of the above claim(s) 18-21, 51 and 52 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 3-14, 16, 17, 29-32, 34-50 is/are rejected.
- 7) ☒ Claim(s) 2, 15 and 33 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Receipt is acknowledged of a reply to the previous Office Action, filed July 17, 2007. Amendments were made to the Specification and Claims.

Claims 1-21 and 29-52 are pending in the instant application. Claims 1-7 and 29-50 are examined. Any rejection of record in the previous Office Action, mailed November 16, 2006 that is not addressed in this action has been withdrawn.

Because this Office Action introduces new rejections other than those set forth in the previous Office Action, and are not necessitated by amendment, this Office Action is **Non-Final**.

Election/Restrictions

This application contains claims 18-21 drawn to an invention nonelected with traverse. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Applicants are traversing the restriction requirement, requesting rejoinder of claims 18-20, arguing that the claims do not comprise different steps. This is not found persuasive because the methods in Groups I and II present different steps. For example, one of the methods of Group II comprises applying a bacteriophage preparation to medical equipment to reduce the incidence of VRE infection; the steps in the method of Group I comprise treating a patient with a pharmaceutical composition containing bacteriophage. Furthermore, the restriction requirement was made final in the last office action.

Art Unit: 1636

New claims 51 and 52 are withdrawn from consideration as being drawn to a non-elected invention. The elected invention is drawn to a method of reducing the risk of bacterial infection, wherein bacteria have already colonized the patient, while claims 51 and 52 are drawn to a method of reducing the risk that persons who have not been colonized will acquire pathogenic bacteria. The patients are at different stages.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 16 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. This rejection is necessitated by amendment.

Claim 16 recites the limitation "the selected bacteria" in line. There is insufficient antecedent basis for this limitation in the claim. The claim should read "the selected pathogenic bacteria" to have proper antecedent basis.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 4, 5, 7-9, 32, 35, 37-39 and 48-50 are rejected under 35 U.S.C. 102(b) as being anticipated by US 6,056,954.

Applicants claim a method for reducing the risk of bacterial infection or reducing the level of colonization in a patient by treating the patient with a bacteriophage composition before the patient develops an illness. The patient is colonized with the pathogenic bacteria, which is from *Hemophilus* or is *Escherichia coli*. The bacteriophage composition can be an oral tablet, liquid, nasal aerosol, throat wash, toothpaste or topical ointment. The topical ointment can be used to treat a wound.

US 6,056,954 (specifically columns 2, 3 and 5) teaches a method of using lytic bacteriophages for preventing those who have been exposed to others who are sick, from becoming infected. The patient is colonized with the pathogenic bacteria, which is from *Hemophilus* or is *Escherichia coli*. The bacteriophage composition can be an oral tablet, liquid, nasal aerosol, throat wash, toothpaste or topical ointment. The topical ointment can be used to treat a wound. Applicant does not define "deep penetrating wound", so the Examiner is interpreting the burns and wounds discussed in column 3 to be deep penetrating wounds.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 3, 6, 10-14, 17, 29-31, 34, 36 and 40-47 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 6,056,954 as applied to claims 1, 4, 5, 7-9, 32, 35, 37-39 and 48-50 above, and in view of Carlton, R. and in further view of Risi et al.

Applicant further teaches that the patient is immunocompromised. The pathogenic bacteria are VRE or MDRSA or multi-drug resistant *Pseudomonas*. The composition can contain a plurality of bacteriophage strains to produce lytic infections against a plurality of bacterial species. The method can also be used to reduce the incidence of bacterial infections of patients admitted to a hospital.

US 6,056,954 teaches all of the limitations as described above. However, it does not teach that the patient is immunocompromised, the pathogenic bacteria are VRE or MDRSA or multi-drug resistant *Pseudomonas*, the composition can contain a plurality of bacteriophage strains to produce lytic infections against a plurality of bacterial species,

or that the method can also be used to reduce the incidence of bacterial infections of patients admitted to a hospital.

Carlton (Archivum Immunologiae et Therapiae Experimentalis 47: 267-274, 1999, specifically pp. 267, 268 and 272) teaches using phage therapy to treat bacterial infections. The pathogenic bacteria treated can be VRE. The composition can contain a grouping of phages to attack more than one bacterial species. Carlton also discloses hospitals routinely applying a topical phage ointment on surgical incisions to prevent infection. However, Carlton does not teach phage therapy for immunocompromised patients, or treating MDRSA or multi-drug resistant *Pseudomonas*.

Risi et al (Am J Infect Control 26: 594-606, 1998, specifically pp. 594, 596, 601) teaches prevention of infection in the immunocompromised patient. The immunocompromised patient could have cystic fibrosis or AIDS (see Box 2 and p. 596). The bacterial infections could be VRE, MDRSA or multi-drug resistant *Pseudomonas*.

The ordinary skilled artisan, desiring to reduce the risk of bacterial infection or reduce the level of colonization in a patient by treating the patient with a bacteriophage composition before the patient develops an illness, would have been motivated to combine the teachings of US 6,056,954 teaching a method of using lytic bacteriophages for preventing those who have been exposed to others who are sick, from becoming infected by pathogenic *Hemophilus* or is *Escherichia coli*, by administering a bacteriophage composition as an oral tablet, liquid, nasal aerosol, throat wash, toothpaste or topical ointment, with the teachings of Carlton teaching using phage therapy to treat VRE infections, with Risi et al teaching prevention of infection in the

Art Unit: 1636

immunocompromised patient, having cystic fibrosis or AIDS because treating a bacterial infection, such as a VRE infection, with bacteriophage is advantageous because Carlton teaches that one phage particle is sufficient to kill a given bacterium and phages are living organisms that can undergo mutations, some of which can overcome bacterial mutations. It would have been obvious to one of ordinary skill in the art to treat an immunocompromised patient with AIDS or cystic fibrosis who has a VRE, MDRSA or drug-resistant *Pseudomonas* because Risi et al teach that infectious diseases represent a major cause of morbidity and mortality in immunocompromised patients. Given the teachings of the prior art and the level of the ordinary skilled artisan at the time of the applicant's invention, it must be considered, absent evidence to the contrary, that said skilled artisan would have had a reasonable expectation of success in practicing the claimed invention.

Allowable Subject Matter


Claims 2, 15 and 33 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michele K. Joike, Ph.D. whose telephone number is 571-272-5915. The examiner can normally be reached on M-F, 9:00-6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michele K Joike, Ph.D.
Examiner
Art Unit 1636


DAVID GUZO
PRIMARY EXAMINER
312